SLXN

Silexion Therapeutics Corp (SLXN) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on developing RNA-interference therapeutics for KRAS-driven cancers, specifically pancreatic cancer (lead candidate SIL-204B). The reporting period includes the consummation of a business combination with Moringa Acquisition Corp (a SPAC) on August 15, 2024. The transaction was accounted for as a reverse recapitalization, with Silexion treated as the accounting acquirer. The company is currently listed on the Nasdaq Global Market under the symbols SLXN (ordinary shares) and SLXNW (warrants).

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no revenue to date.

Material Changes vs. Prior Period

• Expense Surge: Total operating expenses increased by approximately 1,000% year-over-year for the nine-month period, driven primarily by non-cash share-based compensation ($5.86 million YTD 2024 vs. $0.096 million YTD 2023) and one-time transaction costs associated with the SPAC merger.
• Financial Expenses: Net financial expenses rose significantly due to a one-time loss of $4.78 million recorded upon entering the business combination transactions, partially offset by revaluation gains on financial instruments.
• Liquidity Position: Cash and cash equivalents decreased from $4.65 million at the beginning of the nine-month period to $1.97 million at period end, reflecting high operating burn rates despite financing inflows.
• Capital Structure: All redeemable convertible preferred shares were converted into ordinary shares upon the closing of the business combination. The company now has 11.18 million ordinary shares outstanding.

Outlook, Risks, and Contingencies

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Current cash balances are insufficient to fund operations for the next year without additional financing.
• Financing Activities: The company has secured an Equity Line of Credit (ELOC) with White Lion Capital for up to $15 million. As of the report date, $2.5 million had been raised under this facility. A $2.0 million PIPE financing was also completed in connection with the SPAC merger.
• Nasdaq Compliance: On October 29, 2024, the company received a deficiency letter from Nasdaq regarding its stock price falling below the $1.00 minimum bid price requirement. The company has 180 days (until April 28, 2025) to regain compliance.
• Debt Obligations: The company holds promissory notes totaling approximately $4.3 million (fair value), including a $1.25 million convertible note to EarlyBirdCapital and a $3.43 million note to the Sponsor. These are subject to conversion into equity or repayment.
• Geopolitical Risk: The company's headquarters are in Israel. While management states current hostilities have not materially impacted operations, continued conflict could adversely affect operations and capital raising.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $1.97 million cash balance against the projected burn rate, given the explicit "substantial doubt" going concern disclosure.
• Dilution Risk: Assess the potential dilution from the $15 million ELOC facility and the conversion features of the $4.3 million in promissory notes.
• Listing Status: Monitor the company's progress in regaining Nasdaq compliance regarding the $1.00 minimum bid price requirement by April 2025.
• Non-Cash Expenses: Note that a significant portion of the reported losses ($5.86 million YTD) is non-cash share-based compensation, which impacts net loss but not immediate cash flow.
• Product Pipeline: Confirm the status of the lead candidate SIL-204B and the timeline for upcoming clinical trials, as the company has no revenue and relies entirely on future product success.